Skip to main content
. 2023 Apr 17;24(8):7399. doi: 10.3390/ijms24087399
ABT abatacept
ADA adalimumab
BUC bucillamine
CDAI clinical disease activity index
CRP C-reactive protein
CZP certolizumab pegol
DAS disease activity score
ETN etanercept
GLM golimumab
HAQ health assessment questionnaire
IFX infliximab
IGU iguratimod
IgG Immunoglobulin G
KL-6 krebs von den Lungen-6
LDH lactate dehydrogenase
LTBI latent tuberculosis infection
MPDN methylprednisolone
MTX methotrexate
NTM nontuberculous mycobacteriosis
PCP Pneumocystis Pneumonia
PDN prednisolone
RA rheumatoid arthritis
SASP salazosulfapyridine
SDAI simplified disease activity Index
TAC tacrolimus
TCZ tocilizumab
TMP/SMX trimethoprim/sulfamethoxazole
TOF tofacitinib
WBC white blood cells
bDMARDs biological disease modified anti-rheumatic drugs
tsDMARDs targeted synthetic disease modified anti-rheumatic drugs